Scheme of the treatment according to the LNH2007-3B trial. MTX indicates methotrexate; IT, intrathecally; IV, intravenously; AraC, cytosine arabinoside; sc, subcutaneously; and Z-BEAM, carmustine, etoposide, cytarabine, and melphalan with Zevalin (ibritumomab tiuxetan).